Home › Products › Gene function › iDimerize inducible protein interaction systems › Homodimerization systems

Gene function

iDimerize Inducible Homodimer System

The iDimerize Inducible Homodimer System brings protein-protein interactions under real-time, small-molecule control. A protein of interest is fused to the DmrB binding domain, and dimerization is induced by adding the B/B Homodimerizer (identical to the AP20187 ligand). Plasmid and lentiviral (Lenti-X) vector formats are available.

NOTE: While it is possible to use the iDimerize Inducible Homodimer System to induce heterodimerization, you will obtain a mixture of homodimers and heterodimers. To induce heterodimers specifically and exclusively, use the iDimerize Inducible Heterodimer System.

iDimerize Inducible Homodimer Systems (with Tet-On 3G technology)

One challenge of ligand-dependent dimerization experiments is that non-ligand-induced dimerization events may occur if the protein of interest is expressed at high levels. This is especially problematic if the target protein is a membrane protein, because the local concentration can increase quickly due to the limited space on the membrane. We've combined iDimerize and Tet-On 3G technologies to eliminate these unwanted events. First, use doxycycline to optimize the protein's expression to physiologically relevant levels. Then induce dimerization by adding the dimerizer ligand to your culture medium.

More Less

Cat. #

Product

Size

Price

License

Quantity

Details

635069

B/B Homodimerizer

25 mg

$2220.00

License Statement

ID Number

iDimerize and Shield1 Technologies: This product is sold under license from ARIAD Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, for use only in internal research conducted by the buyer, which license expressly excludes the right to sell or otherwise transfer the product to third parties and is expressly made subject to compliance with Takara Bio USA, Inc.’s general Terms and Conditions of Sale and any other restrictions set forth on the product’s web page. No right is given to use this product or its components for any other purpose including, but not limited to diagnostic, therapeutic and/or prophylactic applications for or in human beings, animals and/or plants, including but not limited to gene and cell therapy applications, whether in vitro, ex vivo or in vivo, in foods, drugs, devices or cosmetics of any kind, or for consumption by or use in connection with or administration or application to humans or veterinary treatment of animals, or to provide any services, including research services, to third parties. For information regarding licenses for uses other than internal research, please contact a licensing representative by phone at 650.919.7320 or by e-mail at licensing@takarabio.com.

The B/B Homodimerizer is a membrane-permeant ligand that causes homodimerization of proteins fused to dimerization domain B (DmrB)—provided in the iDimerize Inducible Homodimer System (Cat. No. 635068). NOTE: The B/B Homodimerizer is identical to the AP20187 ligand previously supplied in the ARGENT Regulated Homodimerization Kit from ARIAD Pharmaceuticals, Inc.

Notice to purchaser

Our products are to be used for Research Use Only. They may not be used for any other purpose, including, but not limited to, use in humans, therapeutic or diagnostic use, or commercial use of any kind. Our products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without our prior written approval.

Components

635059

B/B Homodimerizer

5 x 500 uL

$450.00

License Statement

ID Number

Notice to purchaser

Components

635058

B/B Homodimerizer

5 mg

$555.00

License Statement

ID Number

Notice to purchaser

Components

632622

B/B Homodimerizer

4 x 25 mg

$7098.00

License Statement

ID Number

The B/B Homodimerizer is a membrane-permeant ligand that causes homodimerization of proteins fused to dimerization domain B (DmrB)-provided in the iDimerize Inducible Homodimer System (Cat. No. 635068). NOTE: The B/B Homodimerizer is identical to the AP20187 ligand previously supplied in the ARGENT Regulated Homodimerization Kit from ARIAD Pharmaceuticals, Inc.

Notice to purchaser

Components

635088

B/B Washout Ligand

500 uL

$352.00

License Statement

ID Number

This product is covered by U.S. Patent No. 8,173,792.

B/B Washout Ligand is a membrane-permeant ligand that dissociates protein interactions induced by the B/B Homodimerizer, which is provided in each of the iDimerize Inducible Homodimer Systems (Cat. Nos. 635068, 635072, 635084, and 635086). The B/B Washout Ligand dissociates these interactions with a T_1/2 of ~10 minutes after adding it to target cells treated with B/B Homodimerizer.

Notice to purchaser

Components

635068

iDimerize™ Inducible Homodimer System

Each

$1095.00

License Statement

ID Number

The iDimerize Inducible Homodimer System lets you control the homodimerization of a protein of interest in live cells via a membrane permeant compound. The system includes the iDimerize Inducible Homodimer Vector Set 1, which contains two mammalian expression vectors encoding fusion tags that can be easily added to your protein of interest. The activity and localization of the resulting chimeric protein can be controlled by the addition of a small molecule to the cell medium. The system also includes the membrane-permeant compound, B/B Homodimerizer, required for homodimerization, and two linear selection markers for hygromycin and puromycin resistance.

Notice to purchaser

Components

635084

iDimerize™ Inducible Homodimer System (with Tet-On® 3G)

Each

$1195.00

License Statement

ID Number
42	Use of the Tetracycline controllable expression systems (the "Tet Technology") is covered by a series of patents including U.S. Patent # 7541446, # 8383364, # 9181556 , European patents EP # 1200607, # 1954811, #2352833 and corresponding patent claims outside these regions which are proprietary to TET Systems GmbH & Co. KG. Academic research institutions are granted an automatic license with the purchase of this product to use the Tet Technology only for internal, academic research purposes, which license specifically excludes the right to sell, or otherwise transfer, the Tet Technology or its component parts to third parties. Notwithstanding the above, academic and not-for profit research institutions whose research using the Tet Technology is sponsored by for profit organizations, which shall receive ownership to any data and results stemming from the sponsored research, shall need a commercial license agreement from TET Systems in order to use the Tet Technology. In accepting this license, all users acknowledge that the Tet Technology is experimental in nature. TET Systems GmbH & Co. KG makes no warranties, express or implied or of any kind, and hereby disclaims any warranties, representations, or guarantees of any kind as to the Tet Technology, patents, or products. All others are invited to request a license from TET Systems GmbH & Co. KG prior to purchasing these reagents or using them for any purpose. Takara Bio USA, Inc. is required by its licensing agreement to submit a report of all purchasers of the Tet-controllable expression system to TET Systems. For license information, please contact: GSF/CEO TET Systems GmbH & Co. KG, Im Neuenheimer Feld 582 69120 Heidelberg Germany Tel: +49 6221 5880400 Fax: +49 6221 5880404 email: info@tetsystems.com or use the electronic licensing request form via http://www.tetsystems.com/ip-licensing/licensing/for-profit-research
63	Use of this product is covered by one or more of the following U.S. Patent Nos. and corresponding patent claims outside the U.S.: 6,998,115; 7,427,394. This product is intended for research purposes only. It may not be used for (i) any human or veterinary use, including without limitation therapeutic and prophylactic use, (ii) any clinical use, including without limitation diagnostic use, (iii) screening of chemical and/or biological compounds for the identification of pharmaceutically active agents (including but not limited to screening of small molecules), target validation, preclinical testing services, or drug development. Any use of this product for any of the above mentioned purposes requires a license from the Massachusetts Institute of Technology.
99	iDimerize and Shield1 Technologies: This product is sold under license from ARIAD Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, for use only in internal research conducted by the buyer, which license expressly excludes the right to sell or otherwise transfer the product to third parties and is expressly made subject to compliance with Takara Bio USA, Inc.’s general Terms and Conditions of Sale and any other restrictions set forth on the product’s web page. No right is given to use this product or its components for any other purpose including, but not limited to diagnostic, therapeutic and/or prophylactic applications for or in human beings, animals and/or plants, including but not limited to gene and cell therapy applications, whether in vitro, ex vivo or in vivo, in foods, drugs, devices or cosmetics of any kind, or for consumption by or use in connection with or administration or application to humans or veterinary treatment of animals, or to provide any services, including research services, to third parties. For information regarding licenses for uses other than internal research, please contact a licensing representative by phone at 650.919.7320 or by e-mail at licensing@takarabio.com.

The iDimerize Inducible Homodimer System (with Tet-On 3G) lets you control the expression level and dimerization of a protein of interest in live cells. The system includes the iDimerize Inducible Homodimer Vector Set 2, which contains a mammalian expression vector (pTRE3G-Hom1) that allows doxycycline-dependent expression of your protein of interest, tagged with the DmrB domain, in Tet-On 3G transactivator-expressing cells. Homodimerization of the resulting DmrB-tagged protein is controlled by the addition of the B/B Homoodimerizer.

The iDimerize Inducible Homodimer System (with Tet-On 3G) includes vectors and linear selection markers, our highly efficient transfection reagent, Xfect, Tet System Approved FBS, and the B/B Homodimerizer.

Notice to purchaser

Components

635072

Lenti-X™ iDimerize™ Inducible Homodimer System

Each

$1195.00

License Statement

ID Number

cPPT Element. This product and its use are the subject to one or more of the following U.S. Pat. Nos. 6,682,907, 7,981,671, 8,093,042, 8,367,068, 8,460,678, 8,512,994 and foreign equivalents. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot disclose information, sell or otherwise transfer this product, its components or materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for any commercial purposes. If the buyer is not willing to accept the limitations of this limited use statement, Takara Bio USA, Inc. is willing to accept return of the product with a full refund. For information on purchasing a license to the DNA-Flap technology for purposes other than research, contact the Transfer of Technology Office, Institut Pasteur, 28 rue du Docteur Roux, 75 724 Paris Cedex 15 (www.pasteur.fr).

The Lenti-X iDimerize Inducible Homodimer Vector Set 1 is a component of the Lenti-X iDimerize Inducible Homodimer System (Cat. No. 635072). This system enables lentiviral delivery of your gene of interest into a variety of mammalian cells, and the expression of your protein of interest, tagged with a domain allowing for inducible protein homodimerization, via a small molecule "dimerizer".

Notice to purchaser

Components

635086

Lenti-X™ iDimerize™ Inducible Homodimer System (with Tet-On® 3G)

Each

$1768.00

License Statement

ID Number
55	cPPT Element. This product and its use are the subject to one or more of the following U.S. Pat. Nos. 6,682,907, 7,981,671, 8,093,042, 8,367,068, 8,460,678, 8,512,994 and foreign equivalents. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot disclose information, sell or otherwise transfer this product, its components or materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for any commercial purposes. If the buyer is not willing to accept the limitations of this limited use statement, Takara Bio USA, Inc. is willing to accept return of the product with a full refund. For information on purchasing a license to the DNA-Flap technology for purposes other than research, contact the Transfer of Technology Office, Institut Pasteur, 28 rue du Docteur Roux, 75 724 Paris Cedex 15 (www.pasteur.fr).
42	Use of the Tetracycline controllable expression systems (the "Tet Technology") is covered by a series of patents including U.S. Patent # 7541446, # 8383364, # 9181556 , European patents EP # 1200607, # 1954811, #2352833 and corresponding patent claims outside these regions which are proprietary to TET Systems GmbH & Co. KG. Academic research institutions are granted an automatic license with the purchase of this product to use the Tet Technology only for internal, academic research purposes, which license specifically excludes the right to sell, or otherwise transfer, the Tet Technology or its component parts to third parties. Notwithstanding the above, academic and not-for profit research institutions whose research using the Tet Technology is sponsored by for profit organizations, which shall receive ownership to any data and results stemming from the sponsored research, shall need a commercial license agreement from TET Systems in order to use the Tet Technology. In accepting this license, all users acknowledge that the Tet Technology is experimental in nature. TET Systems GmbH & Co. KG makes no warranties, express or implied or of any kind, and hereby disclaims any warranties, representations, or guarantees of any kind as to the Tet Technology, patents, or products. All others are invited to request a license from TET Systems GmbH & Co. KG prior to purchasing these reagents or using them for any purpose. Takara Bio USA, Inc. is required by its licensing agreement to submit a report of all purchasers of the Tet-controllable expression system to TET Systems. For license information, please contact: GSF/CEO TET Systems GmbH & Co. KG, Im Neuenheimer Feld 582 69120 Heidelberg Germany Tel: +49 6221 5880400 Fax: +49 6221 5880404 email: info@tetsystems.com or use the electronic licensing request form via http://www.tetsystems.com/ip-licensing/licensing/for-profit-research
47	Portions of this product are covered by several patent applications owned by, or licensed to, GE Healthcare Dharmacon Inc. The purchase of this product conveys to the buyer the limited, non-exclusive, non-transferable right (without the right to resell, repackage, or further sublicense) under these patent rights to perform the viral infection methods using the lentiviral vectors claimed in those patent applications for research purposes solely in conjunction with this product. No other license is granted to the buyer whether expressly, by implication, by estoppel or otherwise. In particular, the purchase of this product does not include nor carry any right or license to use, develop, or otherwise exploit this product commercially, and no other rights are conveyed to the buyer to use the product or components of the product for any other purposes, including without limitation, provision of services to a third party, generation of commercial databases, or clinical diagnostics or therapeutics. This product is sold pursuant to a license from GE Healthcare Dharmacon Inc, and GE Healthcare Dharmacon Inc., reserves all other rights under these patent rights. For information on purchasing a license to the patent rights for uses other than in conjunction with this product or to use this product for purposes other than research, please contact GE Healthcare Dharmacon Inc., LSlicensing @ge.com.
63	Use of this product is covered by one or more of the following U.S. Patent Nos. and corresponding patent claims outside the U.S.: 6,998,115; 7,427,394. This product is intended for research purposes only. It may not be used for (i) any human or veterinary use, including without limitation therapeutic and prophylactic use, (ii) any clinical use, including without limitation diagnostic use, (iii) screening of chemical and/or biological compounds for the identification of pharmaceutically active agents (including but not limited to screening of small molecules), target validation, preclinical testing services, or drug development. Any use of this product for any of the above mentioned purposes requires a license from the Massachusetts Institute of Technology.
89	This product is protected by U.S. Patent 9,945,850 and additional pending patent. For further license information, please contact a Takara Bio USA licensing representative by email at licensing@takarabio.com.
99	iDimerize and Shield1 Technologies: This product is sold under license from ARIAD Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, for use only in internal research conducted by the buyer, which license expressly excludes the right to sell or otherwise transfer the product to third parties and is expressly made subject to compliance with Takara Bio USA, Inc.’s general Terms and Conditions of Sale and any other restrictions set forth on the product’s web page. No right is given to use this product or its components for any other purpose including, but not limited to diagnostic, therapeutic and/or prophylactic applications for or in human beings, animals and/or plants, including but not limited to gene and cell therapy applications, whether in vitro, ex vivo or in vivo, in foods, drugs, devices or cosmetics of any kind, or for consumption by or use in connection with or administration or application to humans or veterinary treatment of animals, or to provide any services, including research services, to third parties. For information regarding licenses for uses other than internal research, please contact a licensing representative by phone at 650.919.7320 or by e-mail at licensing@takarabio.com.

The Lenti-X iDimerize Inducible Homodimer System (with Tet-On 3G) is a tetracycline-inducible lentiviral gene expression system that lets you control the expression level and dimerization of a protein of interest in live cells. The system includes the pLVX-TRE3G-Hom1 Vector Set, which contains a mammalian expression vector (pLVX-TRE3G-Hom1) that allows doxycycline-dependent expression of your gene of interest, tagged with the DmrB domain, in Tet-On 3G transactivator-expressing cells. Homodimerization of the resulting DmrB-tagged protein is controlled by the addition of the B/B Homodimerizer.

The Lenti-X iDimerize Inducible Homodimer System (with Tet-On 3G) includes vectors and linear selection markers, an optimized packaging system, and the B/B Homodimerizer. The system provides enough reagents for 16 lentiviral packaging reactions.

Notice to purchaser

Components

Overview

Previously available from ARIAD as the ARGENT Regulated Homodimerization Kit
Rapid chemical induction of cell signaling pathways
Activate any pathway or cellular event controlled by homo-oligomers (e.g., dimers, trimers, or tetramers)
Established tool used by over 2,000 research groups, with over 400 scientific publications to date
B/B Homodimerizer is identical to the AP20187 ligand
B/B Washout Ligand reverses protein oligomers that were induced by the B/B Homodimerizer
Plasmid and lentiviral (Lenti-X) vector formats are available

More Information

Applications

Induce any event or pathway that is controlled or activated by protein-protein interactions
Activate signaling pathways in real time
Study transmembrane receptors
Recruit signaling proteins to specific subcellular locations (e.g., the plasma membrane)
Inducible homodimer technology has been used for functional studies of:
- Receptor and non-receptor tyrosine kinases
- Receptor and non-receptor serine/threonine kinases
- Non-kinase receptors
- Signaling proteases
- Adaptor proteins
- Cell adhesion and rolling
- DNA looping
- Activation of recombinase
- RNA splicing
- Protein splicing
- Glycosylation

Product citations

Burnett, S. H. et al. Conditional macrophage ablation in transgenic mice expressing a Fas-based suicide gene. J. Leukoc. Biol. 75, 612–623 (2004).

Freeman, K. W. et al. Inducible prostate intraepithelial neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice. Cancer Res. 63, 8256–63 (2003).

Additional product information

Please see the product's Certificate of Analysis for information about storage conditions, product components, and technical specifications. Please see the Kit Components List to determine kit components. Certificates of Analysis and Kit Components Lists are located under the Documents tab.

Control protein interactions using dimerizer ligands such as AP20187 and AP21967

Instant control of protein-protein interactions in mammalian cells

Every process in the cell is regulated by a complex network of protein-protein interactions. iDimerize technology allows you to specifically, rapidly, and reversibly control the interaction between two proteins simply by adding or removing a small molecule ligand from the culture medium.

iDimerize learning center Technology overview

Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2018 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.

iDimerize Inducible Homodimer System

iDimerize Inducible Homodimer Systems (with Tet-On 3G technology)

Notice to purchaser

Signal transduction example 2

Signal transduction example 1: Inducing a Programmed Cell Death Pathway (Inducible Apoptosis)

Molecular weights of iDimerize ligands

B/B Homodimerizer Cat. # 635069

Notice to purchaser

Molecular structure of the B/B Homodimerizer

Molecular weights of iDimerize ligands

Exploiting fas-mediated apoptosis to induce programmed cell death

Notice to purchaser

Signal transduction example 2

Molecular structure of the B/B Homodimerizer

Signal transduction example 1: Inducing a Programmed Cell Death Pathway (Inducible Apoptosis)

Molecular weights of iDimerize ligands

Exploiting fas-mediated apoptosis to induce programmed cell death

Notice to purchaser

Signal transduction example 2

Signal transduction example 1: Inducing a Programmed Cell Death Pathway (Inducible Apoptosis)

Exploiting fas-mediated apoptosis to induce programmed cell death

His-tag purification TALON metal affinity resins are available in different sizes

Notice to purchaser

B/B Washout Ligand releases B/B Homodimerizer-induced interactions

B/B Washout Ligand can be used to disrupt protein interactions that were induced by the B/B Homodimerizer

Notice to purchaser

How does iDimerize technology work?

Activation of a signal transduction pathway through dimerization of a cell surface receptor protein

Signal transduction example 2

Signal transduction example 1: Inducing a Programmed Cell Death Pathway (Inducible Apoptosis)

Exploiting fas-mediated apoptosis to induce programmed cell death

Notice to purchaser

Notice to purchaser

Notice to purchaser

Overview

More Information

Applications

Product citations

Additional product information